WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE
Search International and National Patent Collections
World Intellectual Property Organization
Search
Browse
Translate
Options
News
Login
Help
⇦ ⇧ ⇨ maximize
34. (WO2012006372) DELIVERY OF RNA TO DIFFERENT CELL TYPES
PCT Biblio. Data
Description
Claims
National Phase
Notices
Drawings
Documents
Latest bibliographic data on file with the International Bureau   
Pub. No.:    WO/2012/006372    International Application No.:    PCT/US2011/043099
Publication Date: 12.01.2012 International Filing Date: 06.07.2011
IPC:
C12N 15/11 (2006.01), C12N 15/113 (2010.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
GEALL, Andrew [GB/US]; (US) (For US Only).
RAMSAUER, Katrin [AT/AT]; (US) (For US Only).
OTTEN, Gillis [US/US]; (US) (For US Only).
MANDL, Christian [AT/US]; (US) (For US Only)
Inventors: GEALL, Andrew; (US).
RAMSAUER, Katrin; (US).
OTTEN, Gillis; (US).
MANDL, Christian; (US)
Agent: LEE, Helen; Novartis Vaccines And Diagnostics, Inc. IP Services M/S X-100B PO Box 8097 Emeryville, CA 94662-8097 (US)
Priority Data:
61/361,780 06.07.2010 US
Title (EN) DELIVERY OF RNA TO DIFFERENT CELL TYPES
(FR) ADMINISTRATION D'ARN À DIFFÉRENTS TYPES CELLULAIRES
Abstract: front page image
(EN)RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
(FR)L'invention concerne un ARN codant pour un immunogène qui est co-administré à des cellules non immunitaires sur le site d'administration et également à des cellules immunitaires qui infiltrent le site d'administration. Les réponses de ces deux types cellulaires vis-à-vis du même ARN administré conduisent à deux effets différents qui interagissent pour produire une réponse immunitaire forte contre l'immunogène. Les cellules non immunitaires traduisent l'ARN et expriment l'immunogène. Les cellules immunitaires s'infiltrant répondent à l'ARN par l'expression d'interférons de type I et de cytokines pro—inflammatoires qui produisent un effet adjuvant local qui agit sur les cellules non immunitaires exprimant l'immunogène pour réguler à la hausse l'expression du complexe majeur d'histocompatibilité, augmentant ainsi la présentation des protéines traduites aux lymphocytes T. Les effets sur les cellules immunitaires et non immunitaires peuvent être réalisés par une administration unique d'un ARN unique, par exemple par une injection unique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)